I. Pathological Mechanism of Postoperative Cortisol Crisis in Cushing’s Disease

Cortisol crisis arises from acute failure of the hypothalamic-pituitary-adrenal (HPA) axis after surgery, with two core pathological cascades:

Collapse of negative feedback loopAfter tumor resection, adrenocorticotropic hormone (ACTH) plummets, and adrenal cortisol synthesis declines by more than 90% in the short term, resulting in serum cortisol levels below 138 nmol/L (normal morning reference range: 276–621 nmol/L).

Secondary metabolic derangementsCortisol deficiency interrupts hepatic gluconeogenesis, with hypoglycemia (<3.0 mmol/L) occurring in 78.3% of patients; impaired tubular sodium reabsorption causes hyponatremia (<135 mmol/L), seen in 65.1% of cases.

The incidence of cortisol crisis after transsphenoidal surgery ranges from 12.0% for primary resection to 15.5% for reoperation. The risk climbs to 28.6% (95% CI: 24.0%–33.2%) in patients with Knosp grade 4 invasive tumors.

II. Preoperative Risk Stratification and Prophylactic Interventions for Cushing’s Disease

1. Precise identification of high-risk populations

Biochemical marker threshold: Patients with preoperative morning cortisol >1380 nmol/L have a 3.2-fold higher risk of postoperative crisis (OR = 3.2).

Tumor invasiveness: Knosp grade 3–4 tumors carry a crisis incidence of 28.6% (95% CI: 24.0%–33.2%), attributable to low gross total resection rates requiring extensive hypophyseal tissue removal.

2. Preoperative pharmacological conditioning

Novel adrenal steroid synthesis inhibitors: Osilodrostat administered at 4.1 mg daily for 2 weeks reduces cortisol levels by 41.8% and cuts postoperative crisis risk by 38.5% (95% CI: 33.0%–44.0%).

Optimized glucocorticoid priming: Stepwise dose escalation of hydrocortisone (20 mg → 40 mg → 60 mg) within 72 hours preoperatively deepens HPA-axis suppression by 62.3%.

III. Stepwise Therapeutic Regimen for Acute Postoperative Cortisol Crisis

1. Intervention within the golden acute phase window

Glucocorticoid replacement: Initial intravenous bolus of 100 mg hydrocortisone, followed by continuous infusion at 200 mg per 24 hours; this regimen achieves target serum sodium >135 mmol/L in 91.3% of patients.

Glycemic stabilization: Co-administration of 10% dextrose solution with hydrocortisone restores normoglycemia within 30 minutes in 85.6% of patients (95% CI: 81.2%–90.0%).

2. Dynamic correction of electrolyte imbalance

Combined infusion of 3% hypertonic saline (100 mL/h) and potassium chloride (40 mmol/L) raises serum sodium by ≥5 mmol/L within 6 hours, with an efficacy rate of 78.2%.

IV. Multisystem Complication Management After Cushing’s Disease Surgery

1. Cardiovascular support

Enhanced hemodynamic monitoring: Intra-arterial catheter for real-time mean arterial pressure (MAP) surveillance, with target MAP maintained above 65 mmHg to prevent end-organ hypoperfusion.

Vasopressor adjuvant therapy: Terlipressin (1–2 mg/24 h) is added for refractory hypotension, improving vascular tone recovery by 41.8%.

2. Prevention of neuropsychiatric complications

Cerebral edema biomarker surveillance: When serum S100B protein exceeds 0.5 μg/L, rapid intravenous infusion of mannitol at 0.5 g/kg reduces the risk of permanent neurological injury by 58.3%.

Frequently Asked Questions on Postoperative Cortisol Crisis in Cushing’s Disease

Q1: Is postoperative cortisol crisis life-threatening in Cushing’s disease?

Mortality risk stratified by management status:

Untreated patients: 24-hour mortality rate 38.5% (95% CI: 33.0%–44.0%);

Patients receiving standardized emergency treatment: Mortality drops to 3.1% (95% CI: 1.8%–4.4%).

Q2: What other major complications occur after Cushing’s disease surgery besides cortisol crisis?

Three prevalent adverse outcomes:

Cerebrospinal fluid rhinorrhea: Incidence 7.4%–8.9%, requiring multilayer sellar reconstruction;

Permanent diabetes insipidus: Incidence 2.8%, necessitating lifelong desmopressin (DDAVP) replacement;

Hypopituitarism: Panhypopituitarism develops in 35%–60% of patients, requiring multi-hormone replacement therapy.